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The Chimera of Population NormsIt was with great interest that we read the recent report by Gilet
and colleagues in the recent edition of Value in Health [1]. Gilet et
al. [1] attempted to develop a normative database for the quality of
life assessment in growth hormone deficient adults (QoL-AGHDA).
Unfortunately, the article demonstrates a number of misunder-
standings of the nature of patient-reported outcome measure-
ment, the value of population norms, and the application of Rasch
analysis.
The QoL-AGHDA is a measure of quality of life (not health-
related quality of life as stated in the article) that is specific to
patients with growth hormone deficiency. Its content was derived
from such patients and was never intended to be completed by
healthy individuals. For the QoL-AGHDA to be valid for use with a
healthy population it would first be necessary to show that it is
psychometrically strong for such a group and that their responses
to the items fit the Rasch model. In order to allow comparisons to
be made between growth hormone deficient (GHD) patients and a
general population it would also be necessary to establish that the
scale works in the same way with both groups. None of these
issues was adequately addressed in the article.
The authors do not indicate whether or not their data fit the
Rasch model – a major omission. If this is not the case the item
order reported in Figure 2 might be invalid. The authors also state
that there are differences between the scores ofmales and females
without reporting whether these differences result from differen-
tial item functioning (DIF). The authors used the software program
RUMM for the Rasch analysis. This program provides different
types of evidence for unidimensionality, including overall fit sta-
tistics and tests for DIF [2].
It is clear from the Person-Item map presented that the QoL-
AGHDA, as expected, is totally unsuitable for use with a healthy
population. Approximately half of the healthy population sample
has less impairment than is measured by the items in the ques-
tionnaire, which accounts for the large basement effect observed.
The map also reveals that the scale has marked redundancy for
this sample. The highly biased scores would prevent reference
values based on means being produced. In the absence of a com-
parison of scaling properties between their sample and a sample
of GHDpatients, no conclusions can be drawnabout the possibility
of establishing normative values.
The concept of producing norms in thisway is also of debatable
scientific merit. It is an attempt to compare apples with pears.
Why should healthy individuals fit on a scale of the “impact of
GHD on the quality of life of adults”? Similarly, why should they fit
on the same scale as patients with other chronic diseases as rec-
ommended by the authors? This problem applies equally to the
application of anymeasure – including generic health statusmea-
sures such as the Short Form 36 health survey, NottinghamHealth
Profile, or EuroQol five-dimensional (EQ-5D) questionnaire. Such
measures cannot be used to make valid comparisons between
healthy and diseased populations or between groups of patientswith different illnesses. The whole concept of normative values is
also questionable in scaling terms due to the existence of DIF be-
tween the multiple sub-populations in the reference sample.
However, Rasch analysis does provide a means for making
valid comparisons between the impacts of different diseases. This
involves making disease-specific measures based on the same
measurement model and applying co-calibration of scores on the
different scales. Interestingly, the QoL-AGHDA uses the needs-
basedmodel of quality of life [3,4], which is the only widely opera-
tionalized model in the field of patient-reported outcome mea-
surement [5,6]. The needs-based model has been employed in the
development of over 30 disease-specific quality of life measures.
Such a body of measures begins to provide a means for making
valid comparisons between diseases. Furthermore, by using a sim-
ilarmethodology, valid comparable utility values can be generated
specific to different diseases. In this way the utilities derived from
the quality of life scales are able to avoid the weaknesses of the
generic utility measures such as the EQ-5D that have limited re-
producibility and responsiveness.
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